Menu
Menu
Precision medicine is transforming healthcare, particularly in oncology, by enabling treatment strategies tailored to the unique characteristics of each tumor. At the heart of this shift lies high-quality biomarker testing, driven by advanced technologies like next-generation sequencing (NGS). As NGS becomes increasingly essential for the successful development and commercialization of innovative therapies, it plays a key role in driving enhanced patient outcomes.
In this audio, Jess Lambe, VP & Managing Director BioPharma Business Development, SOPHiA GENETICS, and Louis Welebob, Ph.D, SVP, Companion Diagnostics, Myriad Genetics, uncover the details of our groundbreaking collaboration. Together, they explain how our unique hybrid testing approach has the potential to accelerate innovation and drive meaningful clinical and commercial impact, reshaping the future of cancer care.
In this session, you will:
Disclaimer notice
© 2026 SOPHiA GENETICS. All rights reserved.
The term SOPHiA used by the speakers refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are those of the speakers and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. This session contains information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
